Lv11
10 积分 2023-03-10 加入
384P Prevalence of fibroblast growth factor receptor 2b (FGFR2b) protein overexpression in squamous non-small cell lung cancer (sqNSCLC)
2小时前
待确认
Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases
2小时前
已完结
EP.06.61 FGRF-2: A Prognostic Biomarker and Potential Therapeutic Target in NSCLC
2小时前
求助中
A Comprehensive Analysis of FGF/FGFR Signaling Alteration in NSCLC: Implications in Prognosis and Microenvironment
2小时前
待确认
Role of fibroblast growth factor receptor-2 splicing in normal and cancer cells
3小时前
已完结
384P Prevalence of fibroblast growth factor receptor 2b (FGFR2b) protein overexpression in squamous non-small cell lung cancer (sqNSCLC)
14天前
已完结
Population pharmacokinetics and exposure–response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2‐targeted regimens
30天前
已完结
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)
1个月前
已完结
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
1个月前
已完结
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors
1个月前
已完结
皖公网安备34019202002308
